Table 3.

Antifungal strategies at diagnosis dependent on subsequent AML treatment intensity

	Palliative treatment	Induction chemotherapy
	N = 118	N = 102
Antifungal prophylaxis after AML diagnosis
After IFD, n (%)	9 (7.6)	4 (3.9)
Posaconazole	2 (1.7)	4 (3.9)
Voriconazole	4 (3.4)	–
Isavuconazole	2 (1.7)	–
No prophylaxis	1 (0.8)	–
w/o IFD, n (%)	12 (10.2)	94 (92)
Posaconazole	11 (9.3)	93 (91)
Voriconazole	1 (0.8)	–
Isavuconazol	–	1 (1)
1st line antifungal treatment
Liposomal amphotericin	6 (5.1)	2 (2)
Caspofungin	4 (3.4)	–
Posaconazole	2 (1.7)	–
Voriconazole	2 (1.7)	2 (2)

AML acute myeloid leukemia, IFD invasive fungal disease